SCHEMBL26606475

SCHEMBL26606475

O=C(Nc1nc2ccccc2[nH]1)c1ccc(Oc2ncc(F)cn2)cc1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 13/20 0.69
▸ NPC1 O15118 13/20 0.69
▸ PKM P14618 7/20 0.69
▸ SMN1; SMN2 Q16637 4/20 0.69
▸ TP53 P04637 2/20 0.69
▸ KDM4E B2RXH2 1/20 0.69
▸ HSD17B10 Q99714 1/20 0.69
▸ MEN1 O00255 3/20 0.65
▸ KMT2A Q03164 3/20 0.65
▸ MTOR P42345 1/20 0.64
▸ KLF5 Q13887 3/20 0.61
▸ MAOB P27338 1/20 0.60
▸ ADORA2A P29274 1/20 0.60
▸ SCD O00767 1/20 0.59
▸ OPRK1 P41145 1/20 0.59
▸ MAPT P10636 2/20 0.55
▸ LMNA P02545 2/20 0.55
▸ GAA P10253 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26606553 0.89 RAB9A (0.67) RAB9ANPC1PKMSMN1; SMN2TP53
SCHEMBL26606568 0.86 RAB9A (0.71) RAB9ANPC1PKMSMN1; SMN2TP53
SCHEMBL30334992 0.82 NPC1 (1.00) RAB9ANPC1PKMSMN1; SMN2TP53
SCHEMBL28376644 0.82 NPC1 (1.00) RAB9ANPC1PKMSMN1; SMN2TP53
SCHEMBL11703736 0.81 NPC1 (0.91) RAB9ANPC1PKMSMN1; SMN2TP53
SCHEMBL11207978 0.79 RAB9A (1.00) RAB9ANPC1PKMSMN1; SMN2TP53
SCHEMBL3926899 0.77 NPC1 (1.00) RAB9ANPC1PKMSMN1; SMN2TP53
SCHEMBL26606435 0.76 RAB9A (0.69) RAB9ANPC1PKMSMN1; SMN2TP53
SCHEMBL26606578 0.76 NPC1 (0.69) RAB9ANPC1SMN1; SMN2TP53KDM4E
SCHEMBL29263343 0.76 RAB9A (0.76) RAB9ANPC1PKMSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116897-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-04-11 — — US disclosed
EP-4269394-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT Korea Research Institute of Chemical Technology (KR) 2023-11-01 — — EP disclosed
CN-116829542-A Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient 韩国化学研究院 2023-09-29 — — CN disclosed
WO-2022164135-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT 한국화학연구원 2022-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116897-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT SIRT7, SIRT1, BRD7 RAB9A 2738/4885NPC1 1296/4885PKM 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback